Document Detail

Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.
MedLine Citation:
PMID:  20508519     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: Inflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness of unknown etiology. Current treatments are modestly successful and with significant side-effects. The purpose of this review is to summarize the current understanding of mechanisms of action underlying the anti-inflammatory actions of conjugated linoleic acid (CLA) and n-3 polyunsaturated fatty acids (PUFAs) in IBD.
RECENT FINDINGS: Nutrition-based interventions that target peroxisome proliferator-activated receptors (PPARs) such as dietary CLA and n-3 PUFA have demonstrated anti-inflammatory efficacy in animal models of IBD. Clinical data on n-3 PUFA in IBD remains generally unimpressive, although results of a recent human study demonstrate that IBD remission can be maintained by maintaining the n-3: n-6 ratio more than 0.65 via n-3 PUFA intervention. In mice, CLA prevented inflammation-driven colorectal cancer by activating PPAR gamma and modulating regulatory T cells and macrophages. CLA is the subject of an ongoing clinical study in Crohn's disease patients.
SUMMARY: Compelling evidence demonstrates that n-3 PUFA and CLA prevent or ameliorate IBD in animal models. However, this basic knowledge has not been translated into novel nutrition-based clinical interventions. For both compounds there is an urgent need for placebo-controlled, large-scale, multicenter clinical trials.
Josep Bassaganya-Riera; Raquel Hontecillas
Related Documents :
17168669 - Gamma linolenic acid: an antiinflammatory omega-6 fatty acid.
10365989 - Adaptation of maternal lipid flux to pregnancy: research needs.
8103979 - Interaction of dietary protein and alpha-linolenic acid on polyunsaturated fatty acid c...
2650689 - Dynamics of n-3 and n-6 fatty acids in phospholipids of heart muscle.
1909049 - Dietary n-6 fatty acids inhibit the incorporation of dietary n-3 fatty acids in thrombo...
12184799 - Unraveling lipid metabolism with microarrays: effects of arachidonate and docosahexaeno...
22595119 - Residual activity of chelating agents and their combinations with cetrimide on root can...
23431419 - Metabolic fate of the increased yeast amino acid uptake subsequent to catabolite derepr...
7296349 - Alterations in membrane permeability with trypsin treatment.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in clinical nutrition and metabolic care     Volume:  13     ISSN:  1473-6519     ISO Abbreviation:  Curr Opin Clin Nutr Metab Care     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-12     Completed Date:  2011-02-16     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9804399     Medline TA:  Curr Opin Clin Nutr Metab Care     Country:  England    
Other Details:
Languages:  eng     Pagination:  569-73     Citation Subset:  IM    
Laboratory of Nutritional Immunology and Molecular Nutrition, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Colorectal Neoplasms / drug therapy,  immunology
Dietary Supplements*
Fatty Acids, Omega-3 / pharmacology,  therapeutic use*
Inflammatory Bowel Diseases / drug therapy*,  metabolism
Linoleic Acids, Conjugated / pharmacology,  therapeutic use*
Macrophages / drug effects,  metabolism
Peroxisome Proliferator-Activated Receptors / metabolism*
T-Lymphocytes, Regulatory / drug effects,  metabolism
Grant Support
R01 AT004308-04/AT/NCCAM NIH HHS
Reg. No./Substance:
0/Fatty Acids, Omega-3; 0/Linoleic Acids, Conjugated; 0/Peroxisome Proliferator-Activated Receptors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel c...
Next Document:  Perioperative haemodynamic therapy.